CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 30, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Millennium Pharmaceuticals, Inc. has extended the agreement that provides Millennium with certain rights to test ImmunoGen’s Tumor-Activated Prodrug (TAP) technology with antibodies to specific targets and to license the right to use the technology to develop products on the terms defined in the agreement. This agreement was scheduled to expire March 30, 2006 unless extended by Millennium. It is now scheduled to expire March 30, 2007.
